All In Biotech

Drug Trial Radar · NCT05554627

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II

Last checked: Nov 20, 2026Latest source record: Jan 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 27, 2023

Primary completion

Oct 27, 2023

Study completion Oct 27, 2023

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Sep 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs. adjunctive aripiprazole (ARI) in Veterans with unipolar Treatment Resistant Depression (TRD). This study will assess the efficacy, safety, and acceptability of adjunctive IN ESK in comparison to ARI, one of the best studied and most widely used adjunctive therapies for TRD. The primary hypothesis is that participants receiving adjunctive IN ESK will be significantly more likely to achieve remission after six weeks of treatment as compared to those who receive adjunctive ARI. Depressive symptoms will be assessed by central raters (CR), blinded to treatment assignment, using the clinician rated version of the Quick Inventory of Depressive Symptomatology (QIDS-C16), a well-validated tool that is commonly used and is easily translated across other depression inventory scales. The study is powered to detect an absolute difference in remission rates of 10%, or larger, at 6 weeks. Additional outcomes of interest include symptom reduction across 6 months of randomized therapy, side effects and other tolerability indices, attrition rates and measures of quality of life and cost-effectiveness.

Conditions

  • Depressive Disorder, Major

Interventions

  • EsketamineDrug

    Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.

  • AripiprazoleDrug

    Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quick Inventory of Depressive Symptoms (QUIDS-C16)Time frame: 6 Weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Tuscaloosa VA Medical Center, Tuscaloosa, AL

    Tuscaloosa, Alabama

  • Phoenix VA Health Care System, Phoenix, AZ

    Phoenix, Arizona

  • Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR

    Little Rock, Arkansas

  • VA Long Beach Healthcare System, Long Beach, CA

    Long Beach, California

  • VA Palo Alto Health Care System, Palo Alto, CA

    Palo Alto, California

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California

  • Rocky Mountain Regional VA Medical Center, Aurora, CO

    Aurora, Colorado

  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT

    West Haven, Connecticut

  • CERC (VISN1, West Haven, CT)

    West Haven, Connecticut

  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia

  • Edward Hines Jr. VA Hospital, Hines, IL

    Hines, Illinois

  • Richard L. Roudebush VA Medical Center, Indianapolis, IN

    Indianapolis, Indiana

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    Boston, Massachusetts

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota

  • Kansas City VA Medical Center, Kansas City, MO

    Kansas City, Missouri

  • New Mexico VA Health Care System, Albuquerque, NM

    Albuquerque, New Mexico

  • Asheville VA Medical Center, Asheville, NC

    Asheville, North Carolina

  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC

    Salisbury, North Carolina

  • Cincinnati VA Medical Center, Cincinnati, OH

    Cincinnati, Ohio

  • Louis Stokes VA Medical Center, Cleveland, OH

    Cleveland, Ohio

  • Jackson C. Montgomery VA Medical Center, Muskogee, OK

    Muskogee, Oklahoma

  • Philadelphia MultiService Center, Philadelphia, PA

    Philadelphia, Pennsylvania

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    Pittsburgh, Pennsylvania

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texas

  • Salem VA Medical Center, Salem, VA

    Salem, Virginia

  • William S. Middleton Memorial Veterans Hospital, Madison, WI

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.